When talking about nutrition, EGCG and probiotics are two words that we’ve been hearing a lot about these days. But most consumers don’t know what they are, where they are found and what they do. Some of that mystery was cleared up this week at the 47th Annual Symposia of the American College of Nutrition (ACN) where leading nutrition experts revealed new research about the health benefits of these two ingredients.
Blackwell Publishing is set to break into an exciting new area of clinical psychiatry with its new journal – Early Intervention in Psychiatry. The journal will be launched at the IEPA Conference in Birmingham in October 2006, and will publish its inaugural issue in February 2007.
Snorers Cause Bed Partners to have EEG Arousals (91)Sean Tolhurst, University of Queensland and SNORE Australia – A new study has found that people with sleep apnea cause their bed-partners to have EEG arousals and sleep disturbance. Up until now there has been limited scientific information into how much a patient with Obstructive Sleep Apnea disturbs a sleeping bed partner. This study investigated the impact that snoring and sleep apnea events have on the bed-partner.
Daily cups of tea can help you recover more quickly from the stresses of everyday life, according to a new study by UCL (University College London) researchers. New scientific evidence shows that black tea has an effect on stress hormone levels in the body.
One in four U.S. adults suffer from a diagnosable mental disorder, yet they face barriers to equal access to treatment and preventive health services, public health experts said today at a forum releasing new research examining the impact of mental illness on the nation’s health from the October 2006 issue of the American Journal of Public Health.
Researchers will report results of a follow-on study of the first non-invasive, diabetes-screening device that was able to significantly outperform the fasting plasma glucose (FPG) test and the A1C test for identifying diabetes and pre-diabetes in individuals with one or more known risk factors for the disease. Presented at the 2006 Scientific Assembly of the American Academy of Family Physicians, held here, the study showed a prototype of the device was able to identify 29% more patients than the FPG test and 17% more patients than the A1C test. Both the FPG and A1C are blood tests used to screen and evaluate patients at risk for diabetes.
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.
UAB (University of Alabama at Birmingham) researchers are investigating whether a common but usually harmless virus can be used to treat a particularly devastating type of brain tumor called malignant glioma. The virus — respiratory enteric orphan virus, or reovirus — inhabits the lungs and intestines of humans. By adulthood, most humans have been exposed to it but demonstrate no illness or effects from the infection.
Pfizer Inc said today that the European Commission has approved Champix(R) (varenicline), a novel pill for smoking cessation in adults. In addition, because smokers often need considerable support to quit successfully, Champix will be available with a patient support plan which smokers can customize to address their individual behavioral triggers as they try to quit smoking.
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved, after a Priority Review, two additional uses for Rituxan(R) (Rituximab) for patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL). One new indication for Rituxan is for first-line treatment of previously-untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. The second new indication is for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.